Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Shares Outstanding (Weighted Average) (2019 - 2026)

Enliven Therapeutics has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $62.8 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Weighted Average) at $62.8 million for Q1 2026, up 25.47% from a year ago — trailing twelve months through Mar 2026 was $62.8 million (up 25.47% YoY), and the annual figure for FY2025 was $56.7 million, up 20.38%.
  • Shares Outstanding (Weighted Average) reached $62.8 million in Q1 2026 per ELVN's latest filing, up from $56.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $62.8 million in Q1 2026 and bottomed at $2.9 million in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $42.0 million (2024), compared with a mean of $37.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) tumbled 85.58% in 2022 before it surged 1323.85% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $3.1 million in 2022, then surged by 1037.74% to $35.5 million in 2023, then skyrocketed by 32.43% to $47.1 million in 2024, then grew by 20.38% to $56.7 million in 2025, then increased by 10.83% to $62.8 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ELVN at $62.8 million in Q1 2026, $56.7 million in Q4 2025, and $54.8 million in Q3 2025.